title: Cancer vaccines: should we be targeting patients with less aggressive disease?
abstract: There is enthusiasm for using vaccines to stimulate the immune system to treat cancer. In this article, the authors review the evolution of vaccines evaluated in clinical trials, starting with Phase III trials in metastatic disease and progressing to trials in the adjuvant setting. Data from these trials suggest that cancer vaccines may be more effective in patients with lower volume disease, and data from the E75 peptide vaccine trials suggest that vaccines may be most effective in less aggressive disease.
authors.affiliation: Department of Surgery, General Surgery Service, Brooke Army Medical Center, San Antonio, TX, USA.
authors.forename: Diane F
authors.initials: DF
authors.lastname: Hale
authors.forename: G Travis
authors.initials: GT
authors.lastname: Clifton
authors.forename: Alan K
authors.initials: AK
authors.lastname: Sears
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Vreeland
authors.forename: Nathan
authors.initials: N
authors.lastname: Shumway
authors.forename: George E
authors.initials: GE
authors.lastname: Peoples
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Mittendorf
mesh_terms: D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000473:pathology* / Q000628:therapy*; D014611:Vaccination / Q000379:methods*
chemical_list: D019496:Cancer Vaccines